Recruiting

Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast…

ClinicalTrials.gov IDNCT07070128

PhaseNot Applicable

Enrollment800

SponsorAstraZeneca

AgeNo minimum reported

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Neoplasms

About this study

Primary outcomes

Agreement between AI tool results and genetic test results (Through study completion, an average at one year.)

Eligibility information

Inclusion Criteria: * female patients, * aged 18 years or older, * identified as high genetic risk by breast surgeons, * referred to a geneticist, and * who agree to participate in the study. Exclusion Criteria: * male patients, * absence of complete information in the medical records, * patients unaware of their biological family history, and * patients who do not agree to participate in the study.

Study locations

Research Site, Golania, Goiás 74605-020 Brazil
Research Site, Porto Alegre, Rio Grande do Sul 90035-001 Brazil
Research Site, Porto Alegre, Rio Grande do Sul 90035-903 Brazil

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.